Bedrijfsoverzicht
Rafael Holdings, Inc. is a specialized entity that primarily engages in holding interests in clinical and early-stage pharmaceutical companies, alongside medical device operations within the United States and Israel. The company operates across three distinct segments: Healthcare, Infusion Technology, and Real Estate, positioning it within the broader Real Estate sector under the specific industry of Real Estate Services. In terms of scale, Rafael Holdings, Inc. maintains a market capitalization of $65.54M, generates annual revenue of $1.16M, and employs a workforce of 21 individuals. These financial metrics indicate that the company operates as a micro-cap entity with a relatively modest revenue base, suggesting a niche focus on high-potential but early-stage biotechnology and medical technology investments rather than mass-market real estate development. The low employee count relative to the sector suggests a lean operational structure typical of holding companies that rely on asset ownership rather than extensive service delivery. The disparity between the market capitalization and the annual revenue further highlights the market's valuation based on future growth potential in the pharmaceutical pipeline rather than current operational earnings.
Financiële gezondheid
Rafael Holdings, Inc. reported a revenue of $1.16M over the trailing twelve months, yet the net income stands at a significant deficit of $-33,106,000, while EBITDA is recorded at $-34,455,000. This substantial gap between the modest revenue figure and the massive net loss reveals a highly aggressive cost structure or significant one-time charges, likely associated with research and development expenses for the early-stage pharmaceutical holdings or write-downs on real estate assets. Despite the negative net income, the company generates a positive free cash flow of $184,250, which indicates a degree of financial flexibility by allowing the firm to fund operations without immediate external capital injection. The company holds a cash reserve of $37.78M, which contrasts sharply with its total debt of $660,000, resulting in a debt-to-equity ratio of 0.79. This balance sheet composition suggests a conservative leverage profile where liquid assets significantly exceed obligations, providing a robust buffer against liquidity shocks. The current ratio is 3.44, a metric that indicates strong short-term liquidity and the ability to cover current liabilities with current assets well over three times over. However, the return on equity is -41.4% and the return on assets is -23.8%, metrics that reveal that management is currently destroying shareholder value rather than generating returns on the invested capital base. The profit margin is listed at 0.0%, while the operating margin is an extreme -3154.0%, underscoring the severe unprofitability of the current operational structure relative to the revenue generated.
Waarderingsbeoordeling
The trailing P/E ratio and forward P/E ratio are both marked as N/A, which implies that traditional earnings-based valuation models are not applicable due to the company's persistent net losses. Consequently, the market does not value the stock based on current or expected earnings per share, but rather on alternative metrics that capture the underlying asset value and sales potential. The price-to-book ratio stands at 0.83, indicating that the market is valuing the company at a discount to its book value, suggesting that investors are pricing in significant intangible asset write-downs or a lack of confidence in the recoverable value of the clinical assets. The price-to-sales ratio is exceptionally high at 56.35, while the EV/EBITDA is -0.94, suggesting that valuation is driven entirely by revenue growth expectations and asset holdings rather than profitability. The 52-week high is $3.19 and the 52-week low is $1.12, placing the stock within a wide trading range that reflects high volatility often associated with speculative micro-cap biotech or real estate holdings. The beta value of 0.51 indicates that the stock exhibits lower price volatility relative to the broader market, moving at roughly half the magnitude of the S&P 500 during periods of market turbulence.
Growth & Income
Rafael Holdings, Inc. experienced a revenue growth of 174.0% year-over-year, while earnings growth is listed as N/A due to the company's continued net losses. The fact that revenue is growing while earnings remain negative implies that the company is reinvesting all capital into expansion, development, or asset acquisition rather than achieving profitability from current operations. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all earnings—or rather, all cash flow—to fund its growth initiatives and sustain its clinical and real estate portfolios. This reinvestment strategy is typical for early-stage holding companies that prioritize long-term asset appreciation in the pharmaceutical sector over immediate income distribution to shareholders. The overall growth and income profile is characterized by explosive top-line expansion funded by existing cash reserves, with no current distribution of income to investors, reflecting a high-risk, high-potential-reward investment thesis centered on future biotech breakthroughs and real estate value realization.